UnitedHealthcare Rhinoplasty Coverage Update

Coverage and Medical Necessity Criteria

Coverage-relevant evidence summaries

Clinical and evidence summaries that support when procedures may be considered:

Nasal valve surgical repair: Surgical repair is recognized as a distinct procedure that can improve nasal obstruction symptoms for appropriately selected patients; approaches include cartilage grafting, open repair, suture suspension, implants, or radiofrequency techniques. The evidence base is largely observational and guideline endorsement (AAO-HNS position statement) supports surgery in selected patients.

Well-designed RCTs are limited; choice of technique depends on anatomy and concomitant procedures.

Rhinoplasty (functional/secondary/trauma-related): Functional rhinoplasty can improve nasal respiration and relieve congenital or acquired obstruction; systematic reviews and cohort studies report improvements in NOSE, VAS, and some objective measures though higher-quality prospective studies are recommended.

Timing considerations apply for cleft-related procedures per specialty guidance.

Rhinophyma excision: Multiple operative modalities (e.g., scalpel excision, lasers) show patient satisfaction and symptom improvement for rhinophyma-related obstruction or infection, but studies are small and heterogeneous.

Technique choice depends on patient goals and practitioner expertise.

Absorbable nasal cartilage support implants: Implants such as Latera may reduce lateral wall motion and improve patient-reported obstruction up to 12–24 months in some studies, but overall evidence quality is low with limited long-term comparative data and potential confounding from adjunctive procedures. Adverse events reported ~5% and were generally mild to moderate.

Randomized, sham-controlled and longer-term comparative trials are needed to confirm durability and comparative effectiveness.

Evidence-based eligibility logic

Covered when ALL of the following are met (based on study populations and guidance):

Severity and symptom documentation: Documented clinically significant nasal obstruction or rhinitis using validated symptom scales (e.g., NOSE severe-to-extreme or elevated rTNSS)e.g., NOSE ≥55 or baseline rTNSS ≥6

Supported by enrollment criteria in multiple device and surgical studies.

Failure of medical therapy: Inadequate symptom relief after appropriate medical therapy (nasal steroids, antihistamines, anticholinergics) when applicableExamples: at least 4 weeks of nasal medications for chronic rhinitis studies; conservative management ≥4 weeks for rhinoplasty indications

PNN/cryotherapy and many device trials enrolled patients who failed medical management.

Anatomic or objective confirmation: Objective or clinical confirmation of the target pathology (e.g., dynamic lateral wall collapse for implants, enlarged septal swell body on endoscopy/CT for NSB reduction, or rhinitis symptoms for PNN ablation)

Clinical eligibility for PNN/SPG ablation

Covered when ALL of the following are met (based on study eligibility and society endorsement):

Chronicity and prior management: Chronic rhinitis symptoms present for at least 6 months with inadequate response to prior medical management (e.g., intranasal steroids, antihistamines, anticholinergics or equivalent therapeutic trial)duration >= 6 months

Trials commonly required prior medical therapy before enrollment.

Symptom severity documented: Documented baseline validated symptom score at or above study thresholds (examples: rTNSS >=6 or specified minimum subscores for rhinorrhea/congestion)rTNSS >=6 (commonly used)

Some cryotherapy trials required rTNSS >=4 with subscore minima; RCTs often used rTNSS >=6.

Procedure selection: Treatment modality must match the device/technique evaluated in trials (e.g., cryoablation devices like ClariFix or TCRF devices like RhinAer) and be performed by qualified specialists

Clinical eligibility for TCRF treatment of nasal valve dysfunction

Covered when ALL of the following are met:

Diagnosis and symptoms: Documented nasal valve dysfunction causing nasal airway obstruction with validated baseline symptom/functional score (e.g., NOSE) demonstrating clinically significant obstruction

TCRF studies used NOSE scores and reported clinically meaningful improvements up to 24 months.

Prior conservative management: Failure or intolerance of conservative measures (e.g., medical therapy, nasal dilators) prior to consideration of TCRF treatment

Trials and reviews note reductions in medication/dilator use after TCRF; conservative therapy generally attempted first.

Procedure matches evidence: TCRF is performed with devices and protocols similar to those evaluated in prospective studies and patient selection is consistent with trial populations

Meta-analyses compared TCRF outcomes to functional rhinoplasty and reported comparable short- to mid-term effects.

Evidence summary for TCRF and nasal valve devices

Summary of evidence-based findings relevant to coverage:

RCT evidence for short-term efficacy: Randomized, patient-blinded RCTs (eg, Silvers et al., 2021) demonstrated higher responder rates and greater NOSE score reductions at 3 months for active TCRF versus sham (example: responder 88.3% vs 42.5%; mean NOSE change -42.3 vs -16.8)3-month responder/NOSE outcomes

Limitations include investigator unblinding and short follow-up.

Durability in observational cohorts: Prospective cohort studies and extended follow-ups (Silvers 2024, Yao 2023, Han 2022) report sustained NOSE improvements and high responder rates (≈90%) at 12–24 months in treated cohorts12–24 months follow-up

Many studies lack concurrent control groups and include industry sponsorship.

Systematic reviews and meta-analyses: Systematic reviews/meta-analyses (eg, Kang 2024; Casale 2023; Han 2024) found significant NOSE score improvements but noted heterogeneity, small sample sizes, short follow-up, and potential industry bias

Procedures that are not specifically listed as reconstructive and medically necessary in this policy — including rhinoplasty, nasal valve repair, or rhinophyma excision performed for indications other than those enumerated — will be considered not reconstructive and not medically necessary. The policy requires that coverage be limited to the explicit clinical scenarios described (for example, documented prolonged/prolongent obstructed nasal breathing from nasal valve compromise, rhinophyma causing obstruction or chronic infection, congenital craniofacial anomalies, or rhinoplasty when functional criteria are met); absent those conditions the procedure is excluded from reconstructive coverage.

For nasal valve repair specifically, coverage requires documentation of dynamic or static valve compromise, evidence of improvement with a modified Cottle maneuver, and clear photographic and surgical planning documentation. For rhinoplasty and rhinophyma excision, coverage likewise depends on the stated functional indications, photographic documentation consistent with the clinical exam, prior conservative management where specified, and a procedure plan intended to correct the anatomic cause of obstruction. Procedures done purely for cosmetic reasons, or that do not meet the listed functional criteria, are not considered reconstructive or medically necessary under this policy.

Adjunctive procedures that do not alter nasal shape or appearance are excluded from the AAO‑HNS definition of rhinoplasty and therefore are not considered part of rhinoplasty-specific guideline considerations. When adjunctive maneuvers (for example, limited septal or turbinate procedures) are performed without impact on nasal shape or appearance, they do not meet the rhinoplasty definition used by the guideline and are excluded from rhinoplasty coverage consideration.

Providers should document how any adjunctive procedure relates to the nasal shape or airway function; if the adjunctive procedure does not affect appearance and does not meet the rhinoplasty definition, it will not be treated as a rhinoplasty under guideline-based coverage logic.

Procedures performed primarily for cosmetic reasons or without objective, validated evidence of functional nasal obstruction are not supported by the clinical evidence summarized in this policy and are therefore not covered as reconstructive or medically necessary. Examples include rhinoplasty performed solely to change appearance without documented mechanical nasal airway obstruction, or procedures offered without baseline symptom scores or objective anatomic confirmation.

Clinical studies and coverage criteria expect validated symptom measures (e.g., NOSE, rTNSS) and objective assessments (photographs, endoscopy, or lateral wall motion video) that demonstrate the anatomic or dynamic cause of obstruction. Absent that documentation, requests will not meet the policy's medical necessity requirements.

Long‑term effectiveness (beyond two years) and comparative effectiveness versus established surgical treatments for several device‑based interventions are not established. Health technology assessments and evolving evidence reviews (for example, ECRI and Hayes reviews) found clinically meaningful short‑term improvements in some studies but judged the overall evidence quality to be very low and insufficient to determine comparative benefit.

Because many published studies are single‑arm, of small sample size, industry‑sponsored, or lack long‑term follow‑up, the policy relies on these limitations when determining that long‑term effectiveness and superiority versus alternatives remain unproven for some treatments and devices.

Some device classes—most notably bioabsorbable nasal cartilage support implants—lack robust comparative effectiveness data and are supported primarily by low‑quality studies, case series, and limited randomized data. Systematic reviews and evidence summaries (Hayes; Kim et al.) report limited high‑quality comparative trials and note uncertainty about how implants perform relative to established surgical grafting or open techniques.

As a result, implant use should be justified relative to established alternatives and prior authorization may be requested to confirm that device selection is supported by the clinical record and trial‑based eligibility where applicable.

This policy must be applied in the context of applicable federal, state, and contractual benefit plan terms. When there is a conflict between the policy and specific federal, state, or contractual requirements, those external requirements govern coverage determinations.

Providers and reviewers must check plan‑specific terms before applying this policy and document compliance with any controlling federal, state, or contractual provisions when submitting or adjudicating claims.

The policy identifies specific technologies that are considered unproven and not medically necessary because of insufficient evidence of safety or efficacy. These include absorbable polylactic acid nasal cartilage support implants (e.g., Latera), nasal septal swell body (NSB) reduction, posterior nasal nerve or sphenopalatine ganglion ablation (any method, e.g., RhinAer, ClariFix), and radiofrequency treatment of nasal valves (e.g., VivAer ARC Stylus).

Requests for these technologies will be reviewed in light of the evidence limitations summarized in external assessments; absent high‑quality comparative data and long‑term outcomes, they are listed as not medically necessary in the policy.

Procedures that rely solely on absorbable implants without documentation that the implant provides expected benefit over established techniques are not supported by the evidence base. Evidence reviews note that many implant studies included adjunctive procedures and lacked long‑term randomized comparisons, limiting the ability to conclude that implants alone are superior or durable.

When implant‑only interventions are proposed, documentation should explain why established surgical techniques (for example, autologous cartilage grafting or open functional rhinoplasty) are not appropriate, and prior authorization may be requested to confirm medical necessity given the current evidence limitations.

Several procedures and device interventions lack adequate comparative data, long‑term follow‑up, or high‑quality randomized evidence; examples include many NSB reduction techniques and some device studies summarized in the literature. Systematic reviews and small case series suggest potential benefit in the short term, but the evidence is frequently limited by small sample sizes, single‑arm designs, and inconsistent outcome measures.

Because of these evidence gaps, coverage for such procedures may be restricted or considered investigational until stronger comparative trials and longer follow‑up data demonstrate sustained clinical benefit and acceptable safety profiles.

Hayes' evolving evidence reviews and ECRI assessments concluded that the evidence supporting PNN/SPG ablation procedures (e.g., ClariFix, RhinAer) is limited and provides, at most, minimal or unclear support for their use. While some trials and meta‑analyses report symptom improvement and generally low adverse event rates, reviewers emphasize the small number of randomized trials, variable study quality, and lack of long‑term comparative data.

Given these conclusions, the policy treats PNN/SPG ablation as unproven/not medically necessary in contexts where high‑quality comparative evidence or demonstrated long‑term benefit is required by the applicable benefit plan.

Hayes concluded that minimal support remains for the VivAer temperature‑controlled radiofrequency (TCRF) procedure for nasal valve remodeling, noting that the available studies are generally small, of variable quality, and frequently single‑arm with limited follow‑up. ECRI judged the device to produce clinically significant improvements up to 24 months but classified the overall evidence as very low quality and stated comparative effectiveness versus established treatments could not be determined.

As summarized in evidence reviews, these limitations mean that VivAer/TCRF may be considered investigational or not medically necessary in settings that require strong comparative or long‑term evidence to justify coverage.

Applicable Codes and Coding Notes

Applicable CPT CodesCPT

30117	Excision or destruction (e.g., laser) of intranasal lesion; internal approach.
30120	Excision or surgical planing of skin of nose for rhinophyma.
30400	Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip.
30410	Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip.
30420	Rhinoplasty, primary; including major septal repair.
30430	Rhinoplasty, secondary; minor revision (small amount of nasal tip work).
30435	Rhinoplasty, secondary; intermediate revision (bony work with osteotomies).
30450	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies).
30460	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip only.
30462	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies.

1–10 of 16

1/2

Unlisted and HCPCSCPT | HCPCS

64999	Unlisted procedure, nervous system
L8699	Prosthetic implant, not otherwise specified

Devices/procedures referencedmixed

Latera

Bioabsorbable lateral wall implant (device name referenced)

No explicit codes in this sectionmixed

No codes listed

Applicable Codes (removed/updated)CPT

30999

CPT code 30999 (removed from applicable codes)

Conservative management duration

Minimum duration>= 6 weeks of medical management (e.g., nasal steroids, antihistamines, decongestants)

PurposeRequired to identify prolonged, persistent nasal airway obstruction not responsive to conservative therapy

ExclusionsElimination of drug-induced rhinitis (eg, rhinitis medicamentosa) should be confirmed before labeling obstruction as prolonged/persistent

NOSE score threshold examples

Typical study enrollmentMany implant and TCRF studies enrolled patients with severe-to-extreme NOSE scores (examples: NOSE ≥55)

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization and Coding Review

Prior authorization is recommended for procedures and devices referenced in this policy. Providers must submit prior authorization requests when coverage is subject to plan, state, or federal requirements and should include all requested documentation to support medical necessity.

Confirm whether the member’s benefit plan or state/federal contract requires prior authorization before scheduling procedures.
Include photos demonstrating anatomic and/or dynamic nasal valve collapse (internal and/or external) with deep inspiration when applicable.
Document baseline symptom scores (e.g., NOSE, rTNSS) and prior conservative medical management.
If implants or device-based treatments are planned (absorbable implants, bioabsorbable lateral wall implants, TCRF, PNN/SPG ablation), indicate device type and supporting clinical rationale.

Prior Authorization

Conservative Medical Management Required

Conservative medical management is expected before consideration of device-based or surgical interventions for nasal airway obstruction. Document trials of appropriate therapies and durations.

Clinical Background and Rationale

Nasal airway disorders such as nasal valve dysfunction, rhinophyma, congenital craniofacial anomalies, and septal or bony deformities can produce mechanical nasal airway obstruction that impairs breathing and quality of life. Evaluation should identify anatomic contributors (internal and external nasal valve compromise, septal deviation, turbinate hypertrophy, septal swell body) and exclude or treat reversible causes (allergic rhinitis, rhinosinusitis, medication‑induced rhinitis) prior to surgical intervention.

The clinical context for intervention includes documenting symptom chronicity and severity using validated instruments (for example, NOSE or rTNSS), demonstrating objective or dynamic anatomic findings (photographs, endoscopy, lateral wall motion video), and showing inadequate response to appropriate conservative medical management when specified. Surgical options range from cartilage grafting and open functional rhinoplasty to device‑based approaches (absorbable implants, TCRF) and ablation techniques; selection should be aligned with the primary pathology and available evidence for that modality.

Definitions and Key Terms

Mechanical Nasal Airway Obstruction

DefinitionTrouble breathing through the nose (not snoring) due to a bony or cartilaginous deformity.

ScopeEncompasses obstruction from structural abnormalities of septum, turbinates, nasal bones, or cartilaginous framework

Clinical relevanceIdentifies patients for whom reconstructive surgical interventions may be considered when conservative therapy fails

Prolonged, Persistent Nasal Airway Obstruction

DefinitionTrouble breathing through the nose that has not responded to six weeks of medical management (eg, nasal steroids, antihistamines, decongestants).

Key requirementDrug‑induced rhinitis (eg, rhinitis medicamentosa) should be excluded as the cause of obstruction.

Policy Revision History

2025-06-01codes_updatedLatest

CPT code 30999 was removed from the policy's applicable codes list; supporting information and sections (Description of Services, Clinical Evidence, References) were updated

This policy version reflects several changes documented in the policy history effective 06/01/2025: the prior policy version was archived, descriptions in the Description of Services, Clinical Evidence, and References sections were updated, and CPT code 30999 was removed from the list of applicable codes. The listed applicable codes and prior authorization requirements should be confirmed against the updated coding table and any plan‑specific requirements when submitting authorization requests.

OpenPayer

Rhinoplasty and Other Nasal Procedures (for Pennsylvania Only)